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Abstract In experimental autoimmune encephalomyelitis
(EAE), an animal model for multiple sclerosis (MS), loss
of the blood–brain barrier (BBB) tight junction (TJ) protein
claudin-3 correlates with immune cell infiltration into the
CNS and BBB leakiness. Here we show that sealing BBB
TJs by ectopic tetracycline-regulated expression of the TJ
protein claudin-1 in Tie-2 tTA//TRE-claudin-1 double
transgenic C57BL/6 mice had no influence on immune cell
trafficking across the BBB during EAE and furthermore did
not influence the onset and severity of the first clinical
disease episode. However, expression of claudin-1 did
significantly reduce BBB leakiness for both blood borne
tracers and endogenous plasma proteins specifically around
vessels expressing claudin-1. In addition, mice expressing
claudin-1 exhibited a reduced disease burden during the
chronic phase of EAE as compared to control littermates.
Our study identifies BBB TJs as the critical structure reg-
ulating BBB permeability but not immune cell trafficking
into CNS during EAE, and indicates BBB dysfunction is a
potential key event contributing to disease burden in the
chronic phase of EAE. Our observations suggest that sta-
bilizing BBB barrier function by therapeutic targeting of
TJs may be beneficial in treating MS, especially when anti-
inflammatory treatments have failed.
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Introduction
Under physiological conditions, the blood–brain barrier
(BBB) maintains homeostasis of the central nervous system
(CNS) by restricting uncontrolled diffusion of water solu-
ble molecules from the blood into the CNS and by limiting
immune cell trafficking into the CNS. The BBB is estab-
lished at the level of CNS microvascular endothelial cells,
which are highly specialized to achieve precise control
over the substances that leave or enter the brain. Lack of
fenestrae and an extremely low pinocytotic activity of BBB
endothelial cells inhibit the transcellular passage of mole-
cules across the barrier whereas tight junctions (TJ)
between the brain endothelial cells restrict the paracellular
diffusion of solutes and ions across the BBB [47]. BBB TJs
are unique as in a belt-like region the opposing membranes
of adjacent brain endothelial cells form continuous and
highly interconnected TJ strands, which appear as a chain
of fusion points at the ultrastructural level [10]. In freeze-
fracture electron microscopy analysis the fusion points are
visualized as strands of TJ particles [46]. At the BBB TJ
particles are predominantly associated with the protoplas-
mic membrane leaflets (P-face) as usually observed in
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epithelial cells [46], whereas strands of TJs particles of
peripheral endothelial cells are rather found associated with
the extracellular fracture face (E-face) of the membrane
bilayer. TJ strands or particles are composed of integral
transmembrane proteins [16], of which occludin and the
claudins have been identified to date [40, 41]. Although
structurally unrelated, occludin and the claudins are both
type II transmembrane proteins bearing 4 transmembrane
domains. They are linked to the actin cytoskeleton by TJ
associated cytoplasmic peripheral membrane proteins of
the MAGUK (membrane associated with a guanylyl
kinase-like domain) family, such as zonula occludens
(ZO)-1, ZO-2 and ZO-3 [41, 45]. Occludin is highly
expressed in TJ of the BBB but not in endothelial TJs of
non-neuronal tissues [4, 22], while intact BBB TJs can
form in the absence of occludin in vivo [38]. In contrast to
occludin, claudins have been shown to be sufficient to
induce TJ strands when transfected into fibroblasts [15].
The claudin family is comprised of 24 members, which
form the backbone of TJs by establishing homophilic and
heterophilic interactions via their extracellular loops [26].
The individual claudins display tissue specific expression
patterns and differ in their individual properties in forming
dynamic aqueous pores that allow size- and charge-selec-
tive paracellular diffusion [17]. Within each tissue,
expression of a unique combination of claudins, therefore,
determines the respective paracellular tightness of the TJs
for different solutes. Claudin-5 has been demonstrated to
be the endothelial cell-specific component of TJs strands
[34] and is also expressed in BBB TJs [35]. Upon trans-
fection into fibroblasts claudin-5 induces E-face associated
TJs [34], whereas claudin-3, which is specifically expres-
sed in TJ of CNS but not other endothelial cells [44, 47],
induces P-face associated TJs [16]. This suggests a specific
function for claudin-3 in BBB TJs, which is supported
further by the recent observation that expression of clau-
din-3 correlates with BBB maturation in response to Wnt/
b-catenin signaling during development [30]. Whereas the
exact function of claudin-3 in BBB TJs remains to be
investigated, an essential function for claudin-5 in sealing
BBB TJs against small molecules up to 800 Da has been
demonstrated by genetic deletion of claudin-5 in mice
[35]. In addition to claudin-5 and claudin-3, expression
of claudin-12 has also been described at the BBB [35].
Previous studies have shown immunostaining for clau-
din-1 in brain endothelium [31]. Later studies, however,
which specifically excluded cross-reactivity of anti-clau-
din-1 antibodies with claudin-3 failed to detect any
immunostaining for claudin-1 in CNS parenchymal
microvessels or in primary mouse or human brain
endothelial cells [2, 20, 43, 47]. Thus, the combined
homophilic and heterophilic interactions between clau-
din-3, claudin-5, and probably also claudin-12, at the
BBB seem to be responsible for the unique barrier
function of the BBB TJs [26].
During neurological disorders such as multiple sclerosis
(MS) or its animal correlate experimental autoimmune
encephalomyelitis (EAE), focal loss of BBB integrity is
observed. MS is an inflammatory demyelinating disease of
the CNS, in which a large number of inflammatory cells
gains access to the CNS parenchyma forming perivascular
inflammatory lesions. Lesion formation in MS is known to
be associated with focal BBB dysfunction as visualized by
gadolinium-enhanced magnetic resonance imaging and
occurs early in the pathogenesis of new lesions in MS [24].
Immunohistological analysis of post mortem brain samples
of MS patients has identified BBB TJs as the anatomical
route for BBB leakiness in MS [29]. In these studies,
abnormal distributions of TJ proteins such as occludin and
ZO-1 in brain vessels were found to correlate with
enhanced BBB leakiness for serum proteins [25, 37]. EAE
reliably models the inflammatory phase of MS and BBB
alterations observed in EAE resemble those observed in
MS [1]. We have previously observed the specific loss of
claudin-3 immunostaining from those brain microvessels
that were surrounded by inflammatory infiltrates [47],
suggesting a direct role for inflammatory cells in disrupting
BBB TJs. While much has been learned regarding the
sequential steps of immune cell rolling or capture, adhesion
and crawling on the BBB, the cellular pathways and the
molecular cues mediating immune cell diapedesis across
the BBB are only just being unraveled (summarized in
[6, 19]). BBB TJs could be disrupted by the immune cells
penetrating the BBB on a paracellular route through the
endothelial cell–cell contacts or alternatively, immune cells
might traverse the BBB on a transcellular route through the
brain endothelial cell itself and thus indirectly alter BBB
TJ architecture (summarized in [9]).
In the present study, we therefore aimed to delineate the
role of BBB TJs in immune cell infiltration and focal BBB
leakiness during EAE. Based on our previous observation
of the specific loss of claudin-3 from BBB TJs, we
hypothesized that in brain endothelial cells ectopic
expression of claudin-1, which like claudin-3 induces
P-face associated TJs upon transfection into fibroblasts
[15], might seal BBB TJs and therefore reduce the para-
cellular component of immune cell diapedesis across the
BBB and/or inflammation-induced BBB leakiness. This
notion is supported by previous findings demonstrating that
claudin-1 seals TJs in skin epithelial and lung endothelial
cells [13, 14]. Furthermore, TJ strands induced by claudin-
3 associate with those induced by claudin-1 suggesting that
ectopic expression of claudin-1 in BBB TJs would pro-
ductively integrate into the BBB TJ strands [16]. We,
therefore, established transgenic mouse lines with tetracy-
cline (TET)-regulated endothelial cell-specific expression
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of claudin-1. In two independent transgenic mouse lines,
we observed TET-induced expression of claudin-1 in
30–50% of PECAM-1? CNS microvessels. This partial
expression of claudin-1 in BBB TJs sufficed to lead to a
significant amelioration of chronic but not acute EAE in
double transgenic Tie-2 tTA//TRE–claudin-1 C57BL/6
mice compared to single transgenic littermates.
Materials and methods
Transgene construction
Construction of the Tie-2 tTA vector and production of
transgenic mice was described elsewhere [5]. The murine
claudin-1 cDNA clone (genbank entry AI663222) was
requested from the German Resource Center for Genome
Research (RZPD) and sequenced to verify integrity of the
open reading frame. The claudin-1 inducible construct was
then created by ligating an XhoI/SacII fragment carrying
the tet-response element (TRE from pUHD10-3; H. Bujard,
Heidelberg), a SacII/BglI claudin-1 fragment, a BamHI/
XbaI fragment containing an IRES and the EGFP open
reading frame (from pIRES2-EGFP; Clontech, Palo Alto),
and an XbaI/XhoI fragment containing the bovine growth
hormone poly(A) signal into the XhoI site of pBluescript II.
TRE-claudin-1 transgenic mice were then produced by
pronuclear injection into fertilized mouse oocytes as
described previously [5]. Six TRE-Claudin-1 transgenic
founder animals were created from which five independent
transgenic lines could be raised.
Genotyping
Transgenic mice were genotyped by PCR. The primers
tTA-FW2 (GACGCCTTAGCCATTGAGATG) and tTA-
REV2 (CAGTAGTAGGTGTTTCCCTTTCTTC) amplify
a product of 550 bp in size from the DNA of Tie-2 tTA
transgenic mice.
PCR using the primers CMV-IE FW (CCATAGAA
GACACCGGGACC) and IRES REV2 (AAGCGGCTTCG
GCCAGTAAC) amplifies a product of 700 bp in size from
the DNA of TRE-Claudin-1 transgenic mice.
Mice
C57BL/6 mice were obtained from Harlan (Horst, The
Netherlands). The Tie-2-tTA activator line #7770 was
described before [5]. Double transgenic mice capable of
TET-inducible expression of claudin-1 were obtained by
crossing Tie2 tTA activator transgenic C57BL/6 mice with
responder mice carrying a unidirectional construct for
claudin–1. The experiments shown in the present study
were performed with the TRE-claudin-1 mouse lines
#23949 and #23974 backcrossed to the C57BL/6 back-
ground for at least 7 generations before being used in the
experiments. Double transgenic (Tie-2 tTA//TRE–claudin-
1) mice were obtained by breeding Tie-2-tTA activator
with TRE-claudin-1 responder mice. Mice in matings were
fed with Doxycycline supplemented chow (100 mg/kg;
Provimi Kliba, Kaiseraugst, Switzerland) to suppress
expression of claudin-1 in double transgenic pups during
embryonic development and until weaning at postnatal day
21. Mice were housed in the animal facility of the Uni-
versity of Bern under specific pathogen free conditions in
individually ventilated cages. All animal procedures were
performed in accordance with the Swiss legislation on the
protection of animals and approved by the respective
government authorities.
Antibodies and reagents
The following primary antibodies were used at 10–20 lg/ml
or as supernatants from hybridomas: rat anti-mouse JAM-A
(BV11 and BV12, from E. Dejana, Milan, Italy), rat anti-
mouse PECAM-1 (Mec13.3, BD Pharmingen, Heidelberg,
Germany); rat anti-mouse CD45 (M1/9) and rat anti-human
CD44 (Hermes-1 = 9B5, used as isotype control) (both
from ATCC, Rockville, MA, USA), rabbit anti-mouse
Claudin-5 (from H. Wolburg/H. Kalbacher, Tu¨bingen,
Germany). The following antibodies were obtained from
Zymed, San Francisco, USA via LuBioScience GmbH,
Lucerne, Switzerland: mouse anti-mouse Claudin-5 (35-
2500), rabbit anti-mouse Claudin-1 (51-9000), rabbit anti-
mouse Claudin-3 (34-1700), rabbit anti-mouse Claudin-5
(34-1600), rabbit anit-mouse Occludin (71-1500), rabbit
anti-mouse ZO-1 (61-7300), rabbit anti-mouse ZO-2 (71-
1400). Rabbit anti-human fibronectin (A0245, cross-reacts
with mouse fibronectin) and rabbit anti-von Willebrand
Factor were from DAKO Cytomation, Glostrup, Denmark.
The following secondary antibodies were used at
3–10 lg/ml: Alexa Fluor 488 goat anti-rat, Alexa Fluor 488
goat anti-rabbit (both from Molecular Probes via Invitrogen
via LuBioScience GmbH, Lucerne, Switzerland), Cyanine
Cy3 goat anti-rat, Cyanine Cy3 goat anti-rabbit, Cyanine
Cy3 donkey anti-mouse (all from Jackson Immunoresearch
via Milan Analytica AG, La Roche, Switzerland).
RNA isolation, cDNA synthesis, Gene chip array
and qPCR of purified parenchymal mouse brain
capillaries
Isolation of PECAM-1? parenchymal mouse brain capil-
laries from 4-week-old female C57BL/6 mice (Harlan,
Horst, The Netherlands) and RNA isolation from these
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capillary fragments, cDNA synthesis and gene chip
microarray analysis (Mouse Genome 430 2.0 Array,
Affymetrix UK, High Wycombe, UK) was performed exactly
as described before [32]. qPCR was based on SYBR green
(MasterMix Plus for SYBR Assay I Low ROX, Eurogentec,
Seraing, Belgium) and carried out on an Applied Biosystems
7500 Real-Time PCR system (Applied Biosystems, War-
rington, UK). To compare expression levels of claudin-1
with claudin-5, detection of the endogenous reference probe
targeting the cDNA for s16 ribosomal protein was included
in each experiment (5 experiments total) and set to 1.0
according to the comparative comparative DCT method
(relative expression = 2DCT , DCT value = average CT
value of target-average CT value of endogenous reference).
The following primer pairs were used: s16 ribosomal protein
(Rps16, NM_013647): forward primer GATATTCGGG
TCCGTGTGA, reverse primer TTGAGATGGACTGTCG
GATG, length of PCR product 69 bp; claudin-5
(NM_013805): forward primer ACGGGAGGAGCGCTTT
AC, reverse primer GTTGGCGAACCAGCAGAG, length
of PCR product: 65 bp; claudin-1 (NM_016674): forward
primer ACTCCTTGCTGAATCTGAACAGT, reverse pri-
mer GGACACAAAGATTGCGATCAG, length of PCR
product: 91 bp.
Immunofluorescence stainings
Mice were anesthetized with Isofluorane (Baxter, Arovet
AG, Zollikon, Switzerland) and perfused with cold phos-
phate buffered saline (PBS) through the left ventricle of the
heart. Brains were removed, coronally cut into three pieces,
embedded in Tissue-Tek (OCT compound, Sysmex Digitana
AG, Horgen Switzerland) and snap frozen in an isopentane
bath (2-Methylbutane, Grogg Chemie AG, Stettlen/Deiss-
wil, Switzerland) at -80C. Cryostat sections (6 lm) were
air dried overnight before staining. Sections were fixed for
10 min with ethanol at 4C, followed by 1 min in acetone at
room temperature and rehydrated with Tris buffered saline
(TBS). Sections were blocked with blocking solution con-
taining 5% (w/v) skimmed milk, 0.3% (v/v) Triton X-100
(Fluka via Grogg Chemie AG, Stettlen/Deisswil, Switzer-
land) and 0.04% (w/v) NaN3 in TBS for 20 min. Primary
antibodies were incubated in the same buffer, unless they
were used as supernatants from hybridomas, for 1 h at room
temperature. Following the washes with TBS, sections were
incubated with secondary antibodies diluted in blocking
solution for 1 h at room temperature. Sections were mounted
in Mowiol (Calbiochem via Grogg Chemie AG, Stettlen/
Deisswil, Switzerland). Sections were analyzed using a
Nikon Eclipse E600 microscope connected to a Nikon Dig-
ital Camera DXM1200F with the Nikon ACT-1 Version 2.63
software (Nikon, Egg/ZH, Switzerland).
Induction of EAE in C57BL/6 mice
Active EAE was induced exactly as described before [8] by
subcutaneous injection of 200 lg of myelin oligodendro-
cyte glycoprotein peptide (MOGaa35–55) emulsified in
complete Freund’s adjuvant (incomplete Freund’s adjuvant
(Santa Cruz, Switzerland) supplemented with 4 mg/ml
attenuated Mycobacterium tuberculosis (H37 RA, DIFCO
Laboratories, Detroit, MI) into 8-to 12-week-old female
C57BL/6 wild-type, single, and double transgenic Tie-2
tTA//TRE–claudin-1 mice. 300 ng pertussis toxin from
Bordetella pertussis (LuBioScience GmbH, Switzerland)
per mouse was administered intraperitoneally at days 1 and
3 post-immunization (p.i.). Assessment of clinical disease
activity was performed as described with the following
disease scores: 0 = healthy, 0.5 = limp tail, 1 = hind leg
paraparesis, 2 = hind leg paraplegia, and 3 = hind leg
paraplegia with incontinence [8]. A total of 6 EAE
experiments were performed comparing double and single
transgenic mice of the Tie-2 tTA//TRE–claudin-1 lines
23949 and 23974. Graph Pad Prism 4.0 software was used
to calculate area under the curve (AUC) values of EAE
clinical scores and for subsequent statistical analysis uti-
lizing Mann–Whitney test (non-parametric, unpaired).
In vivo BBB permeability assays
BBB leakiness for the small molecular tracert Hoechst
nuclear stain (HOE 33258, 534D, Calbiochem-Novabio-
chem, Laufelfingen, Switzerland) and for endogenous
fibronectin was assessed in single and double transgenic
Tie-2 tTA//TRE–claudin-1 mice of lines 23949 and 23974
at day 50 post EAE induction. 100 ll of 2% Hoechst
nuclear stain in PBS was injected intravenously into each
mouse. 30 min after dye circulation, mice were decapi-
tated, brains were removed, coronally cut into three pieces,
which were embedded side by side in Tissue-Tek (OCT
compound, Sysmex Digitana AG, Horgen Switzerland) and
snap frozen in an isopentane bath (2-Methylbutane, Grogg
Chemie AG, Stettlen/Deisswil, Switzerland) at -80C.
Brain cryosections of 4 double and 6 single transgenic mice
were immunofluorescently labeled for CD45 and claudin-1.
From each brain at least 10 cryosections (each showing 3
brain sections) were analyzed, with at least 70 lm between
individual sections analyzed. Inflammatory cuffs in the
brain parenchyma were identified by perivascular accu-
mulation of CD45pos cells and subdivided into 4 leakiness
groups according to claudin-1 expression and Hoechst
leakage: claudin-1pos/Hoechstpos, claudin-1pos/Hoechstneg,
claudin-1neg/Hoechstpos and claudin-1neg/Hoechstneg. The
number of inflammatory cuffs was expressed either in
percentage per brain or as a ratio of Hoechstpos to
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Hoechstneg cuffs and statistically analyzed with unpaired t
test (Graph Pad Prism 4.0).
For quantification of endogenous fibronectin (FN) leak-
age across the BBB brain cryosections were performed as
described above on day 50 p.i. of 6 double and 9 single
transgenic Tie-2 tTA//TRE–claudin-1 mice (lines 23949 and
23974). Pairs of serial sections were immunofluorescently
double-stained for CD45/claudin-1 and CD45/fibronectin,
respectively. Per individual brain section-pairs were ana-
lyzed with at least 70 lm between them. Inflammatory cuffs
in the brain parenchyma were identified by perivascular
accumulation of CD45pos cells and subdivided into 4 fibro-
nectin leakiness groups according to claudin-1 expression
and fibronectin leakage: claudin-1pos/fibronectinpos, claudin-
1pos/fibronectinneg, claudin-1neg/fibronectinpos or claudin-
1neg/fibronectinneg. The number of inflammatory cuffs was
expressed either in percentage per brain or as a ratio of
fibronectinpos to fibronectinneg cuffs and statistically ana-
lyzed with unpaired t test (Graph Pad Prism 4.0).
Quantification of inflammatory cuffs
The number of CD45pos inflammatory cellular infiltrates
surrounding CNS blood vessels (‘‘inflammatory cuffs’’)
was counted in a total of 10 double transgenic and 15 single
transgenic Tie-2 tTA//TRE–claudin-1 mice from lines
23949 and 23974 at day 50 post-immunization and were
classified based on their localization as leptomeningeal
cuffs surrounding meningeal vessels, as periventricular
when localized in direct vicinity to the CNS ventricles and
as parenchymal cuffs when surrounding parenchymal
blood vessels. The analysis was restricted to the brain as
merging of parenchymal and meningeal inflammatory
infiltrates in the spinal cord prohibited quantitation of
individual inflammatory cuffs in spatial relation to indi-
vidual blood vessels. The number of inflammatory cuffs
per mouse was calculated as mean number of inflammatory
cuffs per brain section and median number of inflammatory
cuffs for all mice was statistically analyzed using the
Mann–Whitney U test (Graph Pad Prism 4.0).
MOG specific T cell priming
In vitro antigen-recall assays were carried out with
MOGaa35–55-immunized single, and double transgenic Tie-
2 tTA//TRE–claudin-1 mice, as described before [42]. At
day 10 post-immunization, mice were killed and draining
lymph nodes were dissected. Single-cell suspensions were
produced and cells were seeded in 96-well plates at
2 9 105 cells/well in RPMI 1640 supplemented with 10%
FBS (GIBCO, LuBiosience, Lucerne, Switzerland), 10
U/mL penicillin/streptomycin, 2 mM L-glutamine, 1%
nonessential amino acids, 1 mM sodium pyruvate and
0.05 mM b-mercaptoethanol (Grogg Chemie AG).
Increasing concentrations of MOGaa35–55 were used to test
for antigen-specific T cell proliferation. T cell proliferation
induced by cross-linking of CD3 and CD28 with 0.1 lg/ml
of the respective antibodies (clones 145-2C11 and 37.51,
Pharmingen BD Biosciences, Switzerland) was used as a
positive control. T cell proliferation in medium without
antigen or with 10 lg/ml of purified protein derivate of
Mycobacterium tuberculosis (PPD, CFA-component) was
used as negative and adjuvants control, respectively. All
samples were plated in triplicates. [3H]Thymidine
(1 lCi/mL) was added 16 h prior to harvesting the cultures
on glass fiber filters using a cell harvester (Inotech, Dotti-
kon, Switzerland) and incorporation of [3H]thymidine was
measured by liquid scintillation counting.
Statistics
Statistical analysis was performed with Graph Pad Prism
4.0, as described in the corresponding paragraphs.
Results
Expression of tight junction molecules in CNS
microvessels in C57BL/6 mice
Descriptions on the presence or absence of claudin-1 in
tight junctions (TJs) of blood vessels of the brain have been
controversial. To clarify the molecular architecture of brain
endothelial TJs and claudin-1 expression in the brain we
have, therefore, performed a thorough immunofluorescence
analysis for TJ and TJ associated proteins in frozen brain
sections of wild-type C57BL/6 mice differentiating
between their expression in brain parenchymal blood ves-
sels, meningeal blood vessels, the fenestrated choroid
plexus endothelium, the blood-cerebrospinal fluid barrier
forming choroid plexus epithelium and ependymal cells
lining the ventricles (Table 1). As previously shown [47]
we detected occludin, ZO-1 and ZO-2, claudin-3 and
claudin-5 but not claudin-1 localized to TJs of parenchymal
and meningeal blood vessel endothelial cells. Interestingly,
diffuse claudin-1 immunostaining was observed in men-
ingeal blood vessel endothelial cells (Table 1; Fig. 2).
Endothelial cells from choroid plexus fenestrated micro-
vessels lacked occludin, claudin-1 and claudin-3, but
stained positive for claudin-5. Confirming our previous
observations [48] TJs of the choroid plexus epithelium
expressed all molecules analyzed (including claudin-1 and
claudin-2) except claudin-5. Similarly, although ependy-
mal cells lining the ventricles do not form a tight barrier,
they stained positive for all TJ molecules analyzed with the
exception of claudin-5.
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To confirm the absence of claudin-1 expression in
mouse brain endothelial cells, we analyzed claudin-1
mRNA expression from freshly isolated PECAM-1pos brain
parenchymal microvascular fragments by microarray and
quantitative RT-PCR. Both analyses confirmed claudin-5
and the absence of claudin-1 mRNA expression in brain
endothelial cells (Fig. 1; [32]. Microarray data (CEL, CHP,
and RMA files) are available at GEO (accession number
GSE14375).
Establishment and characterization of Tie2-tTA//TRE-
claudin-1 double transgenic mice
To determine the influence of TJ integrity on immune
cell recruitment across the BBB and BBB leakiness
during EAE we established transgenic mice with endo-
thelial cell-specific and TET-inducible expression of
claudin-1 using the TET-OFF system [5]. Inducibility of
claudin-1 expression in responder lines was tested by
mating TRE-claudin-1 mice with Tie-2 tTA activator
mice expressing tTA in an endothelial cell-specific
manner to generate double transgenic mice [5]. Five
TRE-claudin-1 responder mice lines were characterized
for expression of claudin-1 and GFP (11 mice for line
23949, 12 mice for line 23954, 10 mice for line 23970,
19 mice for line 23971 and 8 mice for line 23974).
Whereas expression of GFP was only detected in line
23974, TET-induced expression of claudin-1 was
observed in all five lines. However, only *30% of
PECAM-1? parenchymal vessels displayed positive
staining for TET-regulated claudin-1 correctly localized
to the cell-to-cell junctions (e.g. 61 claudin-1?PECAM-
1? from 182 PECAM-1? brain microvessels in line
23949 and 70 claudin-1?PECAM-1? from 211 PECAM-
1? brain microvessles in line 23974; Fig. 2). TRE-clau-
din-1 responder lines #23949 and #23974 revealed the
highest endothelial expression of claudin-1 and were
chosen for further analysis. Wild-type C57BL/6 mice
(Table 1) and single transgenic mice (Fig. 2) did not
show positive staining for claudin-1 in brain parenchy-
mal vessels, although we detected endogenous junctional
claudin-1 staining in the epithelial cells of the choroid
plexus and diffuse rather than junctional claudin-1
staining in endothelial cells of meningeal vessels.
Double transgenic Tie-2 tTA//TRE-claudin-1 C57BL/6
mice did not show any apparent phenotypic differences in
the overall anatomy of their organs when compared to
single transgenic and wild-type littermates. Histological
analysis of PECAM-1? blood vessels in tissue sections of
the brain, spinal cord and the secondary lymphoid organs
of double transgenic Tie-2 tTA//TRE-claudin-1 C57BL/6
mice revealed no obvious differences in the vascular
architecture of these organs compared to the organs in
single transgenic or wild-type littermates. Moreover, size
and cellular composition of the secondary lymphoid organs
was not altered in double transgenic Tie-2 tTA//TRE-
claudin-1 C57BL/6 mice compared to single transgenic and
wild-type littermates as determined by FACS analysis (data
not shown). Interestingly, TET-induced claudin-1 was not
expressed in high endothelial venules of double transgenic
Tie-2 tTA//TRE-claudin-1 C57BL/6 mice and would,
therefore, not interfere with lymphocyte recirculation to
lymph nodes.
Table 1 Detection of tight
junction proteins by
immunofluorescence staining of
the healthy brain
a Diffuse rather than junctional
staining
Parenchymal blood
vessel endothelium
Meningeal blood
vessel endothelium
Choroid plexus
endothelium
Choroid plexus
epithelium
Ependymal
cells
Claudin-1 – ?a – ? ?
Claudin-2 – – – ? ?
Claudin-3 ? ? – ? ±
Claudin-5 ? ? ? – –
Occludin ? ? – ? ?
ZO-1 ? ? ? ? ?
ZO-2 ? ? ? ? ?
Fig. 1 Claudin-1 is not expressed in parenchymal CNS microvessels.
mRNA expression level of Claudin-1 and Claudin-5 in parenchymal
CNS microvascular endothelial cells was tested by quantitative RT-
PCR with the s16 ribosomal protein (Rps16) set to 1.0. As a source
for RNA mouse brain microvessels were used immediately after their
isolation. Data express mean values of 5 qPCRs carried out in
triplicates ± standard error. b.d. below limit of detection
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Fig. 2 Expression of claudin-1
in the brains of Tie-2 tTA//TRE-
claudin-1 double and single
transgenic mice.
Immunofluorescence staining
for claudin-1? (red) and
PECAM-1? (green) in frozen
brain sections of double
transgenic Tie-2 tTA//TRE–
claudin-1 mice and single
transgenic littermates from line
23949 is shown. Expression of
claudin-1 was detected in
PECAM-1 ? parenchymal
blood vessels in the brain of
Tie-2 tTA//TRE-claudin-1
double transgenic mice but not
in single transgenic littermates.
In addition, diffuse claudin-1
immunostaining was detected in
PECAM-1? vascular
endothelial cells within the
leptomeninges and in cell-
junctions of choroid plexus
epithelial cells in Tie-2 tTA//
TRE-claudin-1 double
transgenic and single transgenic
mice. Scale bar 20 lm
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Ectopic TET-regulated claudin-1 ameliorates chronic
but not acute experimental autoimmune
encephalomyelitis (EAE)
We next asked, if TET-regulated claudin-1, despite limited
expression levels in PECAM-1? brain microvessels, seals
BBB TJs or impacts pathogenesis of MOGaa35–55-induced
EAE. We, therefore, compared EAE development in double
transgenic Tie-2 tTA//TRE-claudin-1 C57BL/6 mice versus
in single transgenic Tie-1tTA or TRE-claudin-1 littermates
(lines #23949 and #23974, respectively). In addition, in the
first 3 experiments wild-type C57BL/6 littermates were
included to test for changes in EAE pathogenesis in single
transgenic C57BL/6 mice (data not shown). No difference in
the day of onset of clinical EAE nor the maximum clinical
score was observed between Tie-2 tTA//TRE-claudin-1
C57BL/6 mice, and single transgenic or wild-type litter-
mates (Fig. 3 and data not shown). In contrast, starting from
day 30 p.i., we observed a significantly milder disease score
for Tie-2 tTA//TRE-claudin-1 C57BL/6 mice as compared to
single transgenic or wild-type littermates (Fig. 3a and data
not shown), resulting in overall milder chronic EAE in Tie-2
tTA//TRE-claudin-1 C57BL/6 mice (Fig. 3b). Combined
with our observation that MOG-specific T cell priming was
unaltered in Tie-2 tTA//TRE-claudin-1 C57BL/6 mice
compared to single transgenic littermates (data not shown),
the data suggest that TET-regulated claudin-1 expression
ameliorates chronic but not acute EAE.
TET-regulated claudin-1 does not influence immune
cell infiltration into the CNS during EAE
To determine if TET-regulated claudin-1 reduces
immune cell infiltration across the BBB, we quantified
CD45? inflammatory infiltrates surrounding PECAM-1?
microvessels (inflammatory cuffs) in brain sections at
day 50 after induction of EAE. Based on brain locali-
zation we categorized inflammatory cuffs in 3 groups:
(1) meningeal cuffs localized around leptomeningeal
vessels, (2) periventricular cuffs localized directly adja-
cent to a ventricle, and (3) parenchymal cuffs localized
around parenchymal brain microvessels. We detected no
difference in the overall number of inflammatory cuffs
present in the brains of Tie-2//TRE-claudin-1 C57BL/6
double transgenic mice versus single transgenic litter-
mates nor in the number or ratio of inflammatory cuffs
in meningeal, periventricular and parenchymal compart-
ments (Fig. 4). Thus, TET-regulated claudin-1 did not
influence immune cell recruitment across the BBB during
EAE. An additional analysis counting 549 and 353
parenchymal cuffs in the brains of two Tie-2//TRE-
claudin-1 C57BL/6 double transgenic mice and 2 single
transgenic littermates, respectively, during the first clin-
ical episode of EAE (day 18 p.i., clinical score 1) further
supports the notion that TET-regulated claudin-1 did not
interfere with the migration of immune cells across the
BBB during EAE.
Fig. 3 TET-regulated claudin-1 ameliorates chronic EAE Active
EAE was induced in Tie2-tTA//TRE-claudin-1 double transgenic
mice and single transgenic littermates from lines 23949 and 23974,
respectively, by subcutaneous immunization with MOGaa35–55 in
CFA. a Data show mean disease scores of 4 animals per group ±
SEM, evaluated daily following induction of EAE. Black line with
open squares indicate single transgenic mice line 23974; dark line
with filled squares indicate double transgenic mice line 23974; gray
line with open circles indicate single transgenic mice line 23949; light
gray line with filled circles indicate double transgenic mice line
23949. One representative experiment out of six comparing a total of
20 Tie2-tTA//TRE-claudin-1 double transgenic mice with 19 single
transgenic mice from line 23974 and 31 double transgenic mice with
33 single transgenic mice from line 23949 is shown. b The area under
the curve (AUC) was calculated from the EAE clinical course of each
mouse between day 30 and day 50 post-immunization. Shown are the
mean AUC values for each group ± SEM. Statistical analysis of
AUC values with the Mann–Whitney test revealed significantly
reduced EAE severity in double transgenic (filled bars) compared to
single transgenic (open bars) mice in both TRE-claudin-1 lines.
*P \ 0.05; **P \ 0.005
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TET-regulated claudin-1 reduces BBB permeability
in chronic EAE
To investigate, if amelioration of chronic EAE in Tie-2
tTA//TRE-claudin-1 C57BL/6 mice correlated with
reduced BBB leakiness, in vivo BBB permeability was
examined using intravenous injection of Hoechst nuclear
dye, which measures BBB permeability at a particular time
point and with high sensitivity due to its small size of
540 Da. Further, staining for endogenous plasma fibro-
nectin, which accumulates in the brain parenchyma over
time during EAE, allows a retrospective view of BBB
leakage.
Hoechst dye was injected intravenously into Tie-2 tTA//
TRE-claudin-1 C57BL/6 mice and single transgenic lit-
termates at day 50 after induction of EAE, after 30 min of
dye circulation, brains were removed, and immunofluor-
escently stained for claudin-1 and for infiltrating
leukocytes with the pan-leukocyte marker CD45. In both
Tie-2 tTA//TRE-claudin-1 C57BL/6 mice and single
transgenic littermates Hoechst dye leakage was restricted
to vessels with concurrent perivascular accumulation of
CD45? leukocytes.
Since Hoechst dye leakage was observed in all
inflammatory cuffs surrounding meningeal brain and peri-
ventricular microvessels, further quantitative analysis was
restricted to parenchymal inflammatory cuffs. In Tie-2
tTA//TRE-claudin-1 C57BL/6 mice as compared to single
transgenic littermates, a significantly increased percentage
of parenchymal inflammatory cuffs around brain micro-
vessels were impermeable to Hoechst dye (Fig. 5a). These
data suggest amelioration of chronic EAE as observed in
Tie-2 tTA//TRE-claudin-1 C57BL/6 mice may be a con-
sequence of claudin-1 mediated tightening of BBB TJs
leading to reduced BBB permeability during chronic EAE.
Therefore, for each microvessel TET-regulated claudin-1
expression was correlated with BBB leakiness to Hoechst
dye. Parenchymal inflammatory cuffs were categorized in 4
groups by junctional claudin-1 expression and Hoechst
leakage as follows: (1) claudin-1pos/Hoechstpos, (2) clau-
din-1pos/Hoechstneg, (3) claudin-1neg/Hoechstpos, and (4)
claudin-1neg/Hoechstneg. All 4 categories of inflammatory
cuffs were observed in Tie-2 tTA//TRE-claudin-1 C57BL/6
mice, whereas only claudin-1neg/Hoechstpos and claudin-
1neg/Hoechstneg inflammatory cuffs were present in single
transgenic littermates (Fig. 5b). As expected, no significant
difference in Hoechstneg/Hoechstpos ratios in claudin-1neg
inflammatory cuffs in Tie-2 tTA//TRE-claudin-1 C57BL/6
mice versus single transgenic littermates was found
(Fig. 5c). In contrast, Hoechstneg/Hoechstpos ratios of
inflammatory cuffs around claudin-1pos versus claudin-1neg
microvessels revealed a significant increase supporting the
conclusion that TET-regulated claudin-1 increases TJ
integrity and reduces BBB leakiness for Hoechst dye in
chronic EAE.
To extend these observations, we additionally assessed
BBB permeability by staining for the endogenous plasma
marker fibronectin, which is found to accumulate around
leaky brain microvessels during EAE. Consistent with
Hoechst dye data Tie-2 tTA//TRE-claudin-1 C57BL/6
mice displayed a significantly increased number of fibro-
nectin-impermeable inflammatory cuffs versus single
transgenic littermates (Fig. 6a). Parenchymal inflammatory
cuffs were again subdivided into 4 groups based on
expression of endothelial expression of claudin-1 and
presence of perivascular fibronectin, with claudin-1neg/
fibronectinneg and claudin-1neg/fibronectinpos inflammatory
cuffs present in both double and single transgenic mice and
claudin-1pos/fibronectinneg and claudin-1pos/fibronectinpos
inflammatory cuffs found only in double transgenic mice
(Fig. 6b). Based on these groups, we quantified the
inflammatory cuffs and calculated the ratio of fibronec-
tinneg/fibronectinpos parenchymal cuffs versus claudin-1
expression as a parameter of BBB tightness (Fig. 6c).
Again as expected, no significant difference in fibronec-
tinneg/fibronectinpos ratios of claudin-1neg inflammatory
cuffs was observed in Tie-2 tTA//TRE-claudin-1 C57BL/6
mice versus single transgenic littermates (Fig. 6c). In
contrast, fibronectinneg/fibronectinpos ratios for claudin-1pos
inflammatory cuffs versus claudin-1neg inflammatory cuffs
revealed a significant increase supporting the conclusion
Fig. 4 TET-regulated claudin-1 does not influence the number of
inflammatory cuffs in the brain. Inflammatory cuffs were counted in a
total of 10 double transgenic (dtg) and 15 single transgenic (stg) Tie2-
tTA//TRE-claudin-1 mice of lines 23974 and 23949 in 168 versus 147
brain sections, respectively. A total of 1020 versus 1338 parenchymal
cuffs (P), 474 versus 510 leptomeningeal cuffs (M) and 197 versus
170 periventricular cuffs (V) in double transgenic versus single
transgenic mice, respectively, are included into the analysis. Each dot
represents the mean number of inflammatory cuffs/per brain section
of one mouse. Horizontal lines depict median for each group. Mann–
Whitney U analysis revealed no significant differences comparing the
number of cuffs in stg versus dtg mice
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Fig. 5 TET-regulated claudin-1 induces BBB tightening for Hoechst
dye in chronic EAE. At the end of an EAE experiment (day 50 p.i.),
Hoechst dye was injected intravenously into 6 single and 4 double
transgenic Tie2-tTA//TRE-claudin-1 mice. Brain cryosections of
these mice were stained for Claudin-1 (red) and CD45 (green).
Leakage of the nuclear dye Hoechst can be observed in blue. a The
mean percentage (±SD) of inflammatory cuffs per brain localized
around Hoechst-impermeable BBB vessels is significantly increased
in double transgenic compared to single transgenic mice. b The
following parenchymal cuffs are shown: inflammatory cuffs in single
and double transgenic mice that localized around BBB vessels that do
not stain positive for TET-regulated laudin-1 and are either permeable
for Hoechst dye or not; and inflammatory cuffs in double transgenic
mice localized around claudin-1-expressing BBB vessels which are
either permeable for Hoechst dye or not. Scale bar 20 lm. c The
mean ratio (±SD) of Hoechst-impermeable to Hoechst-permeable
inflammatory cuffs localized around claudin-1 negative vessels (in
single and double transgenic mice) or claudin-1 positive vessels (in
double transgenic mice) demonstrates highly significant tightening of
the BBB for Hoechst dye in the presence of TET-regulated claudin-1.
*P \ 0.05; ***P \ 0.001
Fig. 6 TET-regulated claudin-1 induces BBB tightening for endog-
enous fibronectin in EAE. Brains of 9 single and 6 double transgenic
TET-claudin-1 mice at day 50 post induction of aEAE were prepared,
cryo-sectioned and stained for CD45 (green) and claudin-1 (red) as
well as for CD45 (green) and fibronectin (red) on consecutive
sections. a The mean percentage (±SD) of inflammatory cuffs per
brain that have formed around fibronectin-impermeable BBB vessels
is significantly increased in double transgenic compared to single
transgenic mice. b Shown are representative parenchymal cuffs in a
double transgenic mouse. One has formed around a claudin-1neg BBB
vessel and is leaky for plasma fibronectin (upper row), one stains
positive for claudin-1 and is impermeable for plasma fibronectin
(lower row). Note that fibronectin-labeling also stains the basement
membranes of BBB vessels. Scale bar 50 lm. c The mean ratio
(±SD) of fibronectin-impermeable to fibronectin-permeable inflam-
matory cuffs that formed around claudin-1neg vessels (in single and
double transgenic mice) or claudin-1pos vessels (in double transgenic
mice) demonstrates highly significant tightening of the BBB for
plasma fibronectin in the presence of transgenic claudin-1. *P \ 0.05;
**P \ 0.005; ***P \ 0.001
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that during EAE, TET-regulated claudin-1 expression
increases TJ integrity thereby reducing BBB leakiness to
fibronectin. Determining the ratio of fibronectinneg/fibro-
nectinpos parenchymal cuffs versus claudin-1 expression in
mice during the first clinical episode of EAE (day 18 p.i.)
confirmed this finding. Taken together, our data demon-
strate that TET-regulated claudin-1 expression reduces
leakiness of brain microvessels surrounded by inflamma-
tory cells to exogenous tracers and endogenous plasma
proteins during EAE.
Discussion
Increased BBB permeability is a characteristic hallmark of
the pathological alterations observed in the CNS in MS and
in its animal model EAE [27]. In fact, breakdown of the
BBB identified by gadolinium-enhanced magnetic reso-
nance imaging is the earliest detectable event in the
development of most new CNS lesions in MS and is known
to be associated with inflammation [24, 28]. Amelioration
of clinical symptoms is observed, when CNS inflammation
resolves and BBB function is restored, supporting the
notion that lesion formation in MS is driven by inflam-
matory processes [28] and suggesting a causal relationship
between inflammatory cell recruitment into the CNS and
BBB dysfunction. Similarly, in EAE, loss of BBB integrity
has been recognized as a fundamental event in pathogen-
esis and further the magnitude of BBB dysfunction has
been correlated with disease severity [11]. The close
association of inflammation-induced BBB dysfunction with
immune cell entry into the CNS has, however, hampered
attempts to elucidate the specific contribution of BBB
dysfunction to MS pathogenesis.
Our present study provides evidence for the specific
contribution of focal BBB leakiness to disease pathogenesis
in EAE and identifies the BBB TJs as potentially critical
structures for the observed BBB dysfunction during EAE.
Specifically, sealing BBB TJs by ectopic expression of
claudin-1 in Tie-2 tTA//TRE-claudin-1 double transgenic
C57BL/6 mice had no influence on immune cell trafficking
across the BBB during EAE and therefore did not influence
the onset nor the severity of the first clinical episode of EAE.
However, expression of TET-regulated claudin-1 signifi-
cantly reduced BBB leakiness for blood borne tracers or
endogenous plasma proteins specifically in claudin-1
expressing vessels. Further, a reduced disease burden in the
chronic phase of EAE was observed in Tie-2 tTA//TRE-
claudin-1 mice compared to control littermates. Our study,
which dissociates BBB leakiness from immune cell traf-
ficking into the CNS during EAE, identifies the BBB TJs as
critical structures regulating BBB permeability, and defines
BBB dysfunction as a potentially crucial underlying event
contributing to the disease burden in the chronic phase of
MS.
Previous studies on post mortem MS brains have already
suggested a relationship of BBB TJ abnormalities with BBB
hyperpermeability in MS. In these studies, evaluation of a
large number of brain vessels by immunofluorescence
staining and semi-quantitative thick-section confocal anal-
ysis demonstrated TJ abnormalities manifested by beading,
interruption or absence of junctional immunostaining or
appearance of diffuse cytoplasmic staining for the TJ pro-
teins ZO-1, occludin and junctional adhesion molecule-A
(JAM-A) in up to 40% of the blood vessels in MS brain tissue
from primary progressive and secondary progressive disease
states [25, 29, 36, 37]. Aberrant TJ morphology observed in
MS brains correlated with enhanced BBB leakiness for
serum proteins, highlighting that BBB TJ disruption under-
lies BBB leakiness in MS [25, 37]. Based on these
observations, these authors have proposed to consider BBB
TJ pathology—besides inflammation and demyelination—a
distinct entity of tissue injury in MS [37].
EAE reliably models the inflammatory phase of MS and a
number of observations support the view that EAE equally
well allows to model the BBB TJ pathology observed in MS.
Mirroring the observations made in MS tissue samples,
disrupted immunostaining for ZO-1 was observed in brain
microvessels within areas of focal inflammatory lesions
before the onset of clinical EAE and was maintained
throughout the clinical disease course [1]. Similarly, we
previously observed a focal loss of claudin-3 immunostain-
ing from brain microvessels surrounded by inflammatory
cells during EAE [47]. Alterations of the molecular com-
position of BBB TJs during EAE were found to be
accompanied by an aberrant junctional morphology detected
at the ultrastructural level, namely pronounced TJ convolu-
tion and thereby an apparent extension of the intercellular
cleft revealing many kissing points [47].
Although the pathological alterations of BBB TJs
described above are indicative of abnormal BBB TJ func-
tion as well, observation of altered distribution or lack of
an individual TJ protein at the BBB in MS and EAE tissues
may not suffice to define BBB TJ pathology or to conclude
on deficient BBB TJ function in vivo. For instance,
occludin has been shown to be expressed at high levels in
brain endothelial cells [4, 22] yet the complete absence is
compatible with the development of intact BBB TJs in vivo
[38]. In contrast expression of specific occludin splice
variants (summarized in [12] or changes in phosphorylation
state may influence BBB TJ function. The latter is sup-
ported by the observation of occludin dephosphorylation in
spinal cord microvessels in a rat model of EAE corre-
sponding with the onset of CNS inflammation [33].
It has been suggested that during MS and EAE immune
cells migrate across the BBB via a paracellular route
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through endothelial cell–cell junctions, thereby causing
BBB leakiness and TJ pathology. This view is supported by
the observation that mice deficient for the cell–cell contact
molecule PECAM-1 develop aggravated EAE due to
impaired BBB cell–cell contact integrity combined with
increased inflammatory cell recruitment across the BBB
into the CNS [18]. On the other hand, there is mounting
evidence that immune cell diapedesis across the BBB
during EAE might rather occur through the endothelial cell
proper, leaving BBB TJs untouched (summarized in [9]).
Therefore, alternative or more complex mechanisms of
inflammation-induced BBB TJ pathology must be consid-
ered. It is conceivable that in the latter scenario soluble
mediators released by immune cells might trigger BBB TJs
alterations as implied by observations showing that at least
in vitro Th17 cells can impair BBB integrity through the
combined production of IL-17A and IL-22 leading to
downregulation of occludin and to a lesser extent of ZO-1
in brain endothelial cells [23]. In addition, CD8 T cells
were shown to initiate BBB TJ disruption in vivo through a
non-apoptotic perforin-dependent mechanism [39].
In the present study, we hypothesized that experimental
sealing of BBB TJs during CNS inflammation would allow
us to determine the contribution of BBB TJs to immune
cell diapedesis across the BBB as compared to inflamma-
tion-induced BBB leakiness during EAE. Our present study
shows that TET-regulated endothelial cell-specific claudin-
1 integrated into BBB TJs and significantly reduced BBB
leakiness for both a small molecular tracer and endogenous
plasma derived fibronectin. Interestingly, although TET-
induced expression of claudin-1 could only be observed in
30–50% of brain vessels, claudin-1 induced sealing of BBB
TJs during EAE was found to significantly ameliorate the
chronic phase of EAE in two independent transgenic
mouse lines. Our results, therefore, provide direct func-
tional evidence identifying BBB TJs as the critical
component in regulating barrier function of the BBB dur-
ing EAE and confirming the notion that continued BBB TJ
alterations are the basis of BBB dysfunction, which con-
tributes to disease pathogenesis in this animal model of
MS.
At the same time, we failed to find any difference in the
overall number or size of inflammatory cuffs detected in the
brains of Tie-2//TRE-claudin-1 double transgenic mice
versus their single transgenic littermates demonstrating that
claudin-1 induced sealing of BBB TJs did not influence
immune cell recruitment across the BBB during EAE.
Unimpeded extravasation of immune cells across the BBB at
sites of claudin-1 expression, therefore, implies a limited
contribution of the paracellular pathway in immune cell
diapedesis across the BBB during EAE and suggests that
transcellular immune cell trafficking across the brain endo-
thelial cells proper suffices to fully establish inflammatory
infiltrates in the CNS. Lack of any significant differences
observed in the onset and severity of the first clinical episode
of EAE between Tie-2//TRE-claudin-1 double transgenic
mice and their single transgenic littermates suggests that the
early phase of EAE pathogenesis is driven by immune cells
infiltrating the CNS and might explain the therapeutic effi-
cacy of drugs such as natalizumab in treating MS because of
their inhibiting this process [7]. Although our study does not
allow the elucidation of the molecular mechanisms initiating
inflammation-induced BBB leakiness in EAE, it provides
experimental in vivo evidence demonstrating that BBB
dysfunction during EAE is due to BBB TJ disruption and
identifies BBB TJ pathology as a specific pathogenetic entity
contributing to overall disease pathogenesis in EAE.
As the degree of demyelination and/or axonal damage
have been described as morphological correlates to
increasing disability in MS and clinical severity of EAE [21],
we undertook an effort to determine if ameliorated chronic
EAE in Tie-2//TRE-claudin-1 C57BL/6 double transgenic
mice was due to reduced CNS pathology. To this end, we
performed preliminary double immunofluorescence stain-
ings comparing macrophage infiltration and axonal injury in
correlation to demyelination in brain and spinal cord sections
of Tie-2//TRE-claudin-1 C57BL/6 double transgenic mice
and single transgenic littermates during chronic EAE.
Immunostaining for F4/80 showed indistinguishable levels
of macrophage accumulation in the CNS of Tie-2//TRE-
claudin-1 C57BL/6 double transgenic mice and single
transgenic littermates. Similarly, immunostaining for MPB
and Luxol Fast Blue staining revealed comparable degrees of
demyelination in brain and spinal cord sections of Tie-2//
TRE-claudin-1 C57BL/6 double transgenic mice and single
transgenic littermates. Furthermore, similar degrees of
enhanced neurofilament immunofluorescence in spinal cord
tissue sections of Tie-2//TRE-claudin-1 C57BL/6 double
transgenic mice and single transgenic littermates were
indicative of comparable levels of axonal pathology. These
observations suggest that claudin-1 induced sealing of BBB
TJs does not readily translate into reduced CNS pathology
but might lead to an improvement of the physiological
conditions in the CNS of Tie-2//TRE-claudin-1 C57BL/6
double transgenic mice sustaining electrical activity and thus
proper function of CNS neurons. Induced sealing of BBB TJs
could reduce edema and radical formation, and/or improve
ion homeostasis in the CNS, and thus lead to a neuropro-
tective outcome.
Persistent endothelial abnormalities and BBB leakage
have been described in primary and secondary progressive
MS [29] indicating the existence of the same pathogenic
axis in patients. In light of the fact that progressing dis-
ability at later time points of the MS disease course is not
prevented by the current anti-inflammatory treatments
available [3], our present findings demonstrating a
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continuous contribution of BBB TJs pathology to EAE
pathogenesis point to therapeutic sealing of BBB TJs as an
attractive alternative for the restoration of BBB function
and eventually CNS homeostasis. The challenges faced for
developing such methods are our present lack of in depth
knowledge on the precise molecular architecture of BBB
TJs as well as our incomplete understanding of the function
and regulation of expression of the individual TJ compo-
nents in BBB TJs. The recent discovery of the Wnt/b-
catenin signaling pathway involved in brain angiogenesis
and claudin-3 expression may open such a novel avenue for
therapeutic stabilization of BBB TJs during CNS
inflammation.
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